Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment

For coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 15–30% of patients are likely to develop COVID-19-related acute respiratory distress syndrome (ARDS). There are still few effective and well-understood therapies available. Novel variants...

Descripción completa

Detalles Bibliográficos
Autores principales: Que, Haiying, Hong, Weiqi, Lan, Tianxia, Zeng, Hao, Chen, Li, Wan, Dandan, Bi, Zhenfei, Ren, Wenyan, Luo, Min, Yang, Jingyun, He, Cai, Zhong, Ailing, Wei, Xiawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789731/
https://www.ncbi.nlm.nih.gov/pubmed/36566328
http://dx.doi.org/10.1038/s41392-022-01283-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789731/
https://www.ncbi.nlm.nih.gov/pubmed/36566328
http://dx.doi.org/10.1038/s41392-022-01283-6

Ejemplares similares